查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1519698

2024-2032 年按治疗类型、应用、最终用户和地区分類的癌症免疫治疗市场报告

Cancer Immunotherapy Market Report by Therapy Type, Application, End User, and Region 2024-2032
出版日期: | 出版商: IMARC | 英文 143 Pages | 商品交期: 2-3个工作天内

价格

IMARC Group年全球癌症免疫治疗市场规模达1,189亿美元。癌症病例数量的不断增加、政府的有利倡议以及医疗保险的广泛普及是推动市场发展的一些关键因素。

全球癌症免疫治疗市场分析：

主要市场驱动因素：由于饮食不均衡和有毒物质的摄入而导致的癌症病例不断增加是推动市场成长的主要因素之一。除此之外，世界各地大众对各种癌症治疗方案的认识不断增强也促进了市场的成长。

主要市场趋势：医疗保险的广泛可用性和便利性，以及医疗保健支出的增加，为行业投资者提供了利润丰厚的成长机会。除此之外，人们对副作用较少的先进治疗解决方案（例如免疫疗法）的日益青睐正在为市场创造积极的前景。

地理格局：从区域层面来看，市场分为北美、亚太、欧洲、拉丁美洲、中东和非洲，其中北美目前在全球市场中占据主导地位。

竞争格局：全球癌症免疫治疗市场的一些领导者包括安进公司、阿斯特捷利康公司、拜耳公司、百时美施贵宝公司、礼来公司、罗氏公司、葛兰素史克公司、强生公司、Merck KGaA、 Novartis AG、Pfizer Inc.、Sanofi SA 和Seagen Inc. 等。

挑战和机会：不同的肿瘤类型反应不同。然而，在某些情况下，尤其是冷肿瘤免疫疗法没有反应，显示存在抗药性。因此，内在或获得性抗药性的发展对于免疫治疗领域的市场参与者来说是一个巨大的挑战，也是一个重大的机会。

全球癌症免疫治疗市场趋势

癌症盛行率增加

全球癌症病例数量的增加主要推动了癌症免疫疗法市场的发展。国际癌症研究机构（IARC）估计，2020年约有1929万名癌症病例。预计到 2030 年，这些病例将增加到 2,458 万例。根据 GLOBOCAN 的数据，2020 年，美国约有 2,281,658 例新诊断癌症病例，612,390 人因癌症死亡。除此之外，肺癌和乳癌是个体中最常见的两种癌症。加拿大癌症协会（CCS）表示，2020年，近29,800名加拿大人被诊断出罹患肺癌，占所有新发癌症病例的13%。预计约 21,200 名加拿大人将死于肺癌，占 2020 年所有癌症死亡人数的 25%。因此，对有效和持久的癌症治疗的需求不断增长，预计将为整个市场提供利润丰厚的成长机会。

新型免疫疗法的批准不断增加

各个主要市场参与者正在广泛投资于研发活动，以开发和引进先进、更有效的免疫疗法。根据国家临床试验（NCT）註册中心的数据，截至 2020 年 9 月 8 日，全球有超过 1,000 项正在进行的临床试验，旨在开发基于免疫疗法的癌症治疗。此外，许多国家的政府当局和相关监管机构正在采取措施加速新型免疫疗法的审批过程，预计将进一步促进市场成长。例如，根据美国癌症研究协会发表的一篇文章，2023年7月，FDA批准quizartinib（Vanflyta）用于治疗新诊断的急性髓性白血病（AML）的不同阶段。 Quizartinib 专注于 FLT3，这是一种在大约三分之一的 AML 病例中发生扭曲的激酶。同样，2021年5月，美国FDA批准安进公司的LUMAKRAS（Sotorasib）用于治疗KRAS G12C患者，该患者涉及突变的局部晚期或转移性非小细胞肺癌（NSCLC）。 LUMAKRAS 是第一个也是唯一一个针对 NSCLC 的标靶治疗药物。预计此类发展将推动未来几年癌症免疫治疗市场的成长。

製药公司与研究机构之间的伙伴关係与合作

主要参与者正在采取各种策略性措施来推出新产品，这为整体市场创造了积极的前景。例如，2023 年 9 月，Immatics 和 Moderna 策略合作开发 Oncology Therapeutics。此次合作包括对 Immatics 研究性 PRAME203 TCRT 与 Moderna 正在开发的 MARTE mRNA 癌症疫苗的结合进行评估。此外，2023年8月，FBD Biologics Limited与上海復宏汉霖达成策略合作，共同推动新型免疫疗法的开发。同样，2023年12月，德国研究机构BioMed X宣布与日本製药公司小野製药有限公司开展一项新的联合研究项目，旨在利用中性粒细胞的抗肿瘤作用来设计下一代免疫疗法。安进公司、阿斯特捷利康公司、拜耳公司和礼来公司等一些市场参与者都参与了併购活动。透过併购活动，这些公司正在扩大其地理范围并进入新的领域。反过来，预计这将在预测期内增加癌症免疫治疗市场的收入。

本报告回答的关键问题

  • 癌症免疫治疗市场有多大？
  • 2024-2032年全球癌症免疫治疗市场的预期成长率是多少？
  • 推动全球癌症免疫治疗市场的关键因素是什么？
  • COVID-19 对全球癌症免疫治疗市场有何影响？
  • 根据治疗类型，全球癌症免疫治疗市场的细分如何？
  • 基于应用的全球癌症免疫治疗市场的细分情况如何？
  • 基于最终用户的全球癌症免疫治疗市场的细分情况如何？
  • 癌症免疫治疗市场最大的地区是哪一个？
  • 全球癌症免疫治疗市场的主要参与者/公司有哪些？

目录

第一章：前言

第 2 章：范围与方法

  • 研究目的
  • 利害关係人
  • 资料来源
    • 主要资源
    • 二手资料
  • 市场预测
    • 自下而上的方法
    • 自上而下的方法
  • 预测方法

第 3 章：执行摘要

第 4 章：简介

  • 概述
  • 主要行业趋势

第 5 章：全球癌症免疫治疗市场

  • 市场概况
  • 市场业绩
  • COVID-19 的影响
  • 市场预测

第 6 章：市场区隔：依治疗类型

  • 单株抗体
    • 市场走向
    • 市场预测
  • 癌症疫苗
    • 市场走向
    • 市场预测
  • 检查点抑制剂
    • 市场走向
    • 市场预测
  • 免疫调节剂
    • 市场走向
    • 市场预测
  • 其他的
    • 市场走向
    • 市场预测

第 7 章：市场区隔：按应用

  • 肺癌
    • 市场走向
    • 市场预测
  • 乳癌
    • 市场走向
    • 市场预测
  • 大肠直肠癌
    • 市场走向
    • 市场预测
  • 黑色素瘤
    • 市场走向
    • 市场预测
  • 摄护腺癌
    • 市场走向
    • 市场预测
  • 头颈癌
    • 市场走向
    • 市场预测
  • 其他的
    • 市场走向
    • 市场预测

第 8 章：市场区隔：依最终用户

  • 医院
    • 市场走向
    • 市场预测
  • 癌症研究中心
    • 市场走向
    • 市场预测
  • 诊所
    • 市场走向
    • 市场预测
  • 其他的
    • 市场走向
    • 市场预测

第 9 章：市场区隔：按地区

  • 北美洲
    • 美国
    • 加拿大
  • 亚太
    • 中国
    • 日本
    • 印度
    • 韩国
    • 澳洲
    • 印尼
    • 其他的
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙
    • 俄罗斯
    • 其他的
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他的
  • 中东和非洲
    • 市场走向
    • 市场细分：按国家/地区
    • 市场预测

第 10 章：SWOT 分析

  • 概述
  • 优势
  • 弱点
  • 机会
  • 威胁

第 11 章：价值链分析

第 12 章：波特五力分析

  • 概述
  • 买家的议价能力
  • 供应商的议价能力
  • 竞争程度
  • 新进入者的威胁
  • 替代品的威胁

第 13 章：价格分析

第14章：竞争格局

  • 市场结构
  • 关键参与者
  • 关键参与者简介
    • Amgen Inc.
    • AstraZeneca plc
    • Bayer AG
    • Bristol-Myers Squibb Company
    • Eli Lilly and Company
    • F. Hoffmann-La Roche AG
    • GSK plc
    • Johnson & Johnson
    • Merck KGaA
    • Novartis AG
    • Pfizer Inc.
    • Sanofi SA
    • Seagen Inc.
Product Code: SR112024A5095

The global cancer immunotherapy market size reached US$ 118.9 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 261.0 Billion by 2032, exhibiting a growth rate (CAGR) of 8.92% during 2024-2032. The growing number of cancer cases, favorable government initiatives, and wide availability of medical insurance represent some of the key factors driving the market.

Global Cancer Immunotherapy Market Analysis:

Major Market Drivers: The increasing cases of cancer on account of a poor balanced diet and consumption of toxic substances is one of the primary factors driving the growth of the market. In addition to this, the growing awareness about various cancer treatment options among the masses across the world is also contributing to the market growth.

Key Market Trends: The wide availability and easy access to medical insurance, along with the increasing healthcare expenditures, is offering lucrative growth opportunities to industry investors. In addition to this, the emerging preference for advanced treatment solutions with fewer side effects, like immunotherapy, is creating a positive outlook for the market.

Geographical Landscape: On a regional level, the market has been classified into North America, Asia-Pacific, Europe, Latin America, and Middle East and Africa, where North America currently dominates the global market.

Competitive Landscape: Some of the leading players in the global cancer immunotherapy market include Amgen Inc., AstraZeneca plc, Bayer AG, Bristol-Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche AG, GSK plc, Johnson & Johnson, Merck KGaA, Novartis AG, Pfizer Inc., Sanofi S.A, and Seagen Inc., among others.

Challenges and Opportunities: Different tumor types respond differently. However, in some cases, especially cold tumors immunotherapy is unresponsive, suggesting the presence of resistance. Hence, the development of intrinsic or acquired resistance is a big challenge as well as a significant opportunity for the market players in the immunotherapy field.

Global Cancer Immunotherapy Market Trends

Increasing Prevalence of Cancer

The rising number of cancer cases across the world is primarily driving the market for cancer immunotherapies. The International Agency for Research on Cancer (IARC) estimated that, in the year 2020, there were about 19.29 million cancer cases. These cases are projected to increase to 24.58 million cases by 2030. Such a substantial growth in cancer cases is augmenting the demand for effective treatment solutions like immunotherapies. According to GLOBOCAN, in 2020, there were approximately 2,281,658 new cancer cases diagnosed and 612,390 deaths due to cancer alone in the United States. In addition to this, lung cancer and breast cancer are two of the most common cancers found among individuals. The Canadian Cancer Society (CCS) stated that in 2020, nearly 29,800 Canadians were diagnosed with lung cancer, which accounted for 13% of all new cancer cases. About 21,200 Canadians were expected to die from lung cancer, which represented 25% of all cancer deaths in 2020. This indicates an inflating need for effective and more advanced cancer immunotherapy. Thus, the increasing demand for effective and lasting cancer treatment is anticipated to offer lucrative growth opportunities to the overall market.

Rising Approval of Novel Immunotherapies

Various key market players are extensively investing in research and development activities to develop and introduce advanced and more effective immunotherapies. According to the National Clinical Trials (NCT) Registry, as of September 8, 2020, there were more than 1,000 ongoing clinical trials across the world for the development of cancer treatment with immune-based therapies. Moreover, government authorities and concerned regulators of numerous nations are taking initiatives to expedite the approval process of novel immunotherapies, which is anticipated to further catalyze the market growth. For instance, according to an article published by the American Association for Cancer Research, in July 2023, the FDA approved quizartinib (Vanflyta) for treating different phases of newly diagnosed acute myeloid leukemia (AML). Quizartinib focuses on FLT3, a kinase that goes twisted in about one-third of AML cases. Similarly, in May 2021, the US FDA approved Amgen's LUMAKRAS (Sotorasib) for the treatment of patients with KRAS G12C, which involves mutated locally advanced or metastatic non-small cell lung cancer (NSCLC). LUMAKRAS is the first and only targeted treatment for NSCLC. Such developments are expected to propel the cancer immunotherapy market growth in the coming years.

Partnerships and Collaborations between Pharmaceuticals and Research Institutions

Various Strategic initiatives are being undertaken by major players to launch new products, which is creating a positive outlook for the overall market. For instance, in September 2023, Immatics and Moderna strategically collaborated to develop Oncology Therapeutics. The collaboration includes an assessment of Immatics investigational PRAME203 TCRT in combination with the MARTE mRNA cancer vaccine being developed by Moderna. Moreover, in August 2023, FBD Biologics Limited and Shanghai Henlius Biotech, Inc. entered into a strategic collaboration to boost the development of new immunotherapies. Similarly, in December 2023, BioMed X, a German research institution, announced a new joint research project with Ono Pharmaceutical Co. Ltd, a Japanese pharmaceutical company, to design next-generation immunotherapies by leveraging the antitumor effects of neutrophils. Several market players, such as Amgen Inc., AstraZeneca plc, Bayer AG, and Eli Lilly and Company, are involved in merger and acquisition activities. Through M&A activity, these companies are expanding their geographic reach and entering new territories. This, in turn, is projected to bolster the cancer immunotherapy market revenue over the forecasted period.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the market report, along with forecasts at the global, regional and country levels from 2024-2032. Our report has categorized the market based on therapy type, application and end user.

Breakup by Therapy Type:

Monoclonal Antibodies

Cancer Vaccines

Checkpoint Inhibitors

Immunomodulators

Others

Currently, monoclonal antibodies hold the majority of the total market share

The report has provided a detailed breakup and analysis of the market based on the therapy type. This includes monoclonal antibodies, cancer vaccines, checkpoint inhibitors, immunomodulators, and others. According to the report, monoclonal antibodies represented the largest segment.

Increasing investment for research and development activities of monoclonal antibodies is opening new avenues for the growth of companies in the oncology therapeutics space. Monoclonal antibodies are extensively being studied for their therapeutic effects against various types of cancers. For instance, in August 2023, FDA approved Talvey to treat adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of treatment, including proteasome inhibitors, immunomodulatory agents and an antiCD38 monoclonal antibody.

Breakup by Application:

Lung Cancer

Breast Cancer

Colorectal Cancer

Melanoma

Prostate Cancer

Head and Neck Cancer

Others

Among these, lung cancer currently exhibits a clear dominance in the market

A detailed breakup and analysis of the market based on the application has also been provided in the report. This includes lung cancer, breast cancer, colorectal cancer, melanoma, prostate cancer, head and neck cancer, and others. According to the report, lung cancer accounted for the largest market share.

According to cancer immunotherapy market overview, the lung cancer segment accounted for the largest revenue share in the market. This can be attributed to the increasing prevalence of lung malignancies, the escalating adoption of immunotherapy, and the presence of a robust pipeline of investigational candidates. Furthermore, rising product approval and new product launches also providing a positive outlook to the market. For instance, in November 2023, the US Food and Drug Administration (FDA) granted marketing authorizations to Augtyro (Bristol, Inc.) for the treatment of locally refractory or metastatic Non-Small Cell Lung Cancer (NSCLC) with Repotrectinib.

Breakup by End User:

Hospitals

Cancer Research Centers

Clinics

Others

Hospitals account for the largest market share

A detailed breakup and analysis of the market based on the end user has also been provided in the report. This includes hospitals, cancer research centers, clinics, and others. According to the report, hospitals accounted for the largest market share.

Growing cases of cancer, increasing treatment rates, along with a large number of hospitals offering immunotherapies are contributing to a rise in the number of patients admitted to a hospital. To treat cancer, hospitals are increasingly utilizing immunotherapies. According to an article published by the National Cancer Institute, in April 2023, in the U.S. 25% of patients died in a hospital, with 62% hospitalized at least once in the last month of life for the cancer treatments.

Breakup by Regional:

North America

United States

Canada

Asia-Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

North America currently dominates the global market.

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America (the United States and Canada) was the largest market for cancer immunotherapy.

The growth in the region can be attributed to the growing number of patients suffering from cancer, the rising development of bioinformatic tools, and favorable government initiatives. According to GLOBOCAN, in the US, there were an estimated 2,281,658 new cancer cases diagnosed and 612,390 deaths due to cancer in the year 2020. Moreover, the presence of key players in this region is also contributing to the growth of the market. According to an article published by Elsevier Ltd., in April 2023, the US National Cancer Institute published its expected national cancer plan, a roadmap, and calls to action on improving all stages of care for those suffering from cancer.

Competitive Landscape:

The market research report has provided a comprehensive analysis of the competitive landscape. Detailed profiles of all major companies have also been provided. Some of the key players in the market include:

Amgen Inc.

AstraZeneca plc

Bayer AG

Bristol-Myers Squibb Company

Eli Lilly and Company

F. Hoffmann-La Roche AG

GSK plc

Johnson & Johnson

Merck KGaA

Novartis AG

Pfizer Inc.

Sanofi S.A

Seagen Inc.

(Please note that this is only a partial list of the key players, and the complete list is provided in the report.)

Global Cancer Immunotherapy Market Recent Developments

December 2023: Oxford University Hospitals launched a new mRNA cancer vaccine trial for patients with head and neck cancers.

December 2023: BioMed X, a German research institution announced a new joint research project with Ono Pharmaceutical Co. Ltd, a Japanese pharmaceutical company, to design next-generation immunotherapies by leveraging the antitumor effects of neutrophils.

July 2023: Spanish researchers at Cima University of Navarra developed a new immunotherapy combination for liver cancer. This therapy improves efficacy in animal models of hepatocellular carcinoma. This is a proof of concept that lays the foundations for the application of this treatment in patients with the most common liver cancer.

Key Questions Answered in This Report

  • 1. How big is the cancer immunotherapy market?
  • 2. What is the expected growth rate of the global cancer immunotherapy market during 2024-2032?
  • 3. What are the key factors driving the global cancer immunotherapy market?
  • 4. What has been the impact of COVID-19 on the global cancer immunotherapy market?
  • 5. What is the breakup of the global cancer immunotherapy market based on the therapy type?
  • 6. What is the breakup of the global cancer immunotherapy market based on the application?
  • 7. What is the breakup of the global cancer immunotherapy market based on end user?
  • 8. Which is the largest region in the cancer immunotherapy market?
  • 9. Who are the key players/companies in the global cancer immunotherapy market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Cancer Immunotherapy Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Therapy Type

  • 6.1 Monoclonal Antibodies
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Cancer Vaccines
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Checkpoint Inhibitors
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Immunomodulators
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast
  • 6.5 Others
    • 6.5.1 Market Trends
    • 6.5.2 Market Forecast

7 Market Breakup by Application

  • 7.1 Lung Cancer
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Breast Cancer
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Colorectal Cancer
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Melanoma
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast
  • 7.5 Prostate Cancer
    • 7.5.1 Market Trends
    • 7.5.2 Market Forecast
  • 7.6 Head and Neck Cancer
    • 7.6.1 Market Trends
    • 7.6.2 Market Forecast
  • 7.7 Others
    • 7.7.1 Market Trends
    • 7.7.2 Market Forecast

8 Market Breakup by End User

  • 8.1 Hospitals
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Cancer Research Centers
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Clinics
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast
  • 8.4 Others
    • 8.4.1 Market Trends
    • 8.4.2 Market Forecast

9 Market Breakup by Region

  • 9.1 North America
    • 9.1.1 United States
      • 9.1.1.1 Market Trends
      • 9.1.1.2 Market Forecast
    • 9.1.2 Canada
      • 9.1.2.1 Market Trends
      • 9.1.2.2 Market Forecast
  • 9.2 Asia-Pacific
    • 9.2.1 China
      • 9.2.1.1 Market Trends
      • 9.2.1.2 Market Forecast
    • 9.2.2 Japan
      • 9.2.2.1 Market Trends
      • 9.2.2.2 Market Forecast
    • 9.2.3 India
      • 9.2.3.1 Market Trends
      • 9.2.3.2 Market Forecast
    • 9.2.4 South Korea
      • 9.2.4.1 Market Trends
      • 9.2.4.2 Market Forecast
    • 9.2.5 Australia
      • 9.2.5.1 Market Trends
      • 9.2.5.2 Market Forecast
    • 9.2.6 Indonesia
      • 9.2.6.1 Market Trends
      • 9.2.6.2 Market Forecast
    • 9.2.7 Others
      • 9.2.7.1 Market Trends
      • 9.2.7.2 Market Forecast
  • 9.3 Europe
    • 9.3.1 Germany
      • 9.3.1.1 Market Trends
      • 9.3.1.2 Market Forecast
    • 9.3.2 France
      • 9.3.2.1 Market Trends
      • 9.3.2.2 Market Forecast
    • 9.3.3 United Kingdom
      • 9.3.3.1 Market Trends
      • 9.3.3.2 Market Forecast
    • 9.3.4 Italy
      • 9.3.4.1 Market Trends
      • 9.3.4.2 Market Forecast
    • 9.3.5 Spain
      • 9.3.5.1 Market Trends
      • 9.3.5.2 Market Forecast
    • 9.3.6 Russia
      • 9.3.6.1 Market Trends
      • 9.3.6.2 Market Forecast
    • 9.3.7 Others
      • 9.3.7.1 Market Trends
      • 9.3.7.2 Market Forecast
  • 9.4 Latin America
    • 9.4.1 Brazil
      • 9.4.1.1 Market Trends
      • 9.4.1.2 Market Forecast
    • 9.4.2 Mexico
      • 9.4.2.1 Market Trends
      • 9.4.2.2 Market Forecast
    • 9.4.3 Others
      • 9.4.3.1 Market Trends
      • 9.4.3.2 Market Forecast
  • 9.5 Middle East and Africa
    • 9.5.1 Market Trends
    • 9.5.2 Market Breakup by Country
    • 9.5.3 Market Forecast

10 SWOT Analysis

  • 10.1 Overview
  • 10.2 Strengths
  • 10.3 Weaknesses
  • 10.4 Opportunities
  • 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

  • 14.1 Market Structure
  • 14.2 Key Players
  • 14.3 Profiles of Key Players
    • 14.3.1 Amgen Inc.
      • 14.3.1.1 Company Overview
      • 14.3.1.2 Product Portfolio
      • 14.3.1.3 Financials
      • 14.3.1.4 SWOT Analysis
    • 14.3.2 AstraZeneca plc
      • 14.3.2.1 Company Overview
      • 14.3.2.2 Product Portfolio
      • 14.3.2.3 Financials
      • 14.3.2.4 SWOT Analysis
    • 14.3.3 Bayer AG
      • 14.3.3.1 Company Overview
      • 14.3.3.2 Product Portfolio
      • 14.3.3.3 Financials
      • 14.3.3.4 SWOT Analysis
    • 14.3.4 Bristol-Myers Squibb Company
      • 14.3.4.1 Company Overview
      • 14.3.4.2 Product Portfolio
      • 14.3.4.3 Financials
      • 14.3.4.4 SWOT Analysis
    • 14.3.5 Eli Lilly and Company
      • 14.3.5.1 Company Overview
      • 14.3.5.2 Product Portfolio
      • 14.3.5.3 Financials
      • 14.3.5.4 SWOT Analysis
    • 14.3.6 F. Hoffmann-La Roche AG
      • 14.3.6.1 Company Overview
      • 14.3.6.2 Product Portfolio
      • 14.3.6.3 SWOT Analysis
    • 14.3.7 GSK plc
      • 14.3.7.1 Company Overview
      • 14.3.7.2 Product Portfolio
      • 14.3.7.3 Financials
      • 14.3.7.4 SWOT Analysis
    • 14.3.8 Johnson & Johnson
      • 14.3.8.1 Company Overview
      • 14.3.8.2 Product Portfolio
      • 14.3.8.3 Financials
      • 14.3.8.4 SWOT Analysis
    • 14.3.9 Merck KGaA
      • 14.3.9.1 Company Overview
      • 14.3.9.2 Product Portfolio
      • 14.3.9.3 Financials
      • 14.3.9.4 SWOT Analysis
    • 14.3.10 Novartis AG
      • 14.3.10.1 Company Overview
      • 14.3.10.2 Product Portfolio
      • 14.3.10.3 Financials
      • 14.3.10.4 SWOT Analysis
    • 14.3.11 Pfizer Inc.
      • 14.3.11.1 Company Overview
      • 14.3.11.2 Product Portfolio
      • 14.3.11.3 Financials
      • 14.3.11.4 SWOT Analysis
    • 14.3.12 Sanofi S.A
      • 14.3.12.1 Company Overview
      • 14.3.12.2 Product Portfolio
      • 14.3.12.3 Financials
      • 14.3.12.4 SWOT Analysis
    • 14.3.13 Seagen Inc.
      • 14.3.13.1 Company Overview
      • 14.3.13.2 Product Portfolio
      • 14.3.13.3 Financials
      • 14.3.13.4 SWOT Analysis

List of Figures

  • Figure 1: Global: Cancer Immunotherapy Market: Major Drivers and Challenges
  • Figure 2: Global: Cancer Immunotherapy Market: Sales Value (in Billion US$), 2018-2023
  • Figure 3: Global: Cancer Immunotherapy Market Forecast: Sales Value (in Billion US$), 2024-2032
  • Figure 4: Global: Cancer Immunotherapy Market: Breakup by Therapy Type (in %), 2023
  • Figure 5: Global: Cancer Immunotherapy Market: Breakup by Application (in %), 2023
  • Figure 6: Global: Cancer Immunotherapy Market: Breakup by End User (in %), 2023
  • Figure 7: Global: Cancer Immunotherapy Market: Breakup by Region (in %), 2023
  • Figure 8: Global: Cancer Immunotherapy (Monoclonal Antibodies) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 9: Global: Cancer Immunotherapy (Monoclonal Antibodies) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 10: Global: Cancer Immunotherapy (Cancer Vaccines) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 11: Global: Cancer Immunotherapy (Cancer Vaccines) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 12: Global: Cancer Immunotherapy (Checkpoint Inhibitors) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 13: Global: Cancer Immunotherapy (Checkpoint Inhibitors) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 14: Global: Cancer Immunotherapy (Immunomodulators) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 15: Global: Cancer Immunotherapy (Immunomodulators) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 16: Global: Cancer Immunotherapy (Other Therapy Types) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 17: Global: Cancer Immunotherapy (Other Therapy Types) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 18: Global: Cancer Immunotherapy (Lung Cancer) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 19: Global: Cancer Immunotherapy (Lung Cancer) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 20: Global: Cancer Immunotherapy (Breast Cancer) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 21: Global: Cancer Immunotherapy (Breast Cancer) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 22: Global: Cancer Immunotherapy (Colorectal Cancer) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 23: Global: Cancer Immunotherapy (Colorectal Cancer) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 24: Global: Cancer Immunotherapy (Melanoma) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 25: Global: Cancer Immunotherapy (Melanoma) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 26: Global: Cancer Immunotherapy (Prostate Cancer) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 27: Global: Cancer Immunotherapy (Prostate Cancer) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 28: Global: Cancer Immunotherapy (Head and Neck Cancer) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 29: Global: Cancer Immunotherapy (Head and Neck Cancer) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 30: Global: Cancer Immunotherapy (Other Applications) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 31: Global: Cancer Immunotherapy (Other Applications) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 32: Global: Cancer Immunotherapy (Hospitals) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 33: Global: Cancer Immunotherapy (Hospitals) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 34: Global: Cancer Immunotherapy (Cancer Research Centers) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 35: Global: Cancer Immunotherapy (Cancer Research Centers) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 36: Global: Cancer Immunotherapy (Clinics) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 37: Global: Cancer Immunotherapy (Clinics) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 38: Global: Cancer Immunotherapy (Other End Users) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 39: Global: Cancer Immunotherapy (Other End Users) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 40: North America: Cancer Immunotherapy Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 41: North America: Cancer Immunotherapy Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 42: United States: Cancer Immunotherapy Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 43: United States: Cancer Immunotherapy Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 44: Canada: Cancer Immunotherapy Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 45: Canada: Cancer Immunotherapy Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 46: Asia-Pacific: Cancer Immunotherapy Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 47: Asia-Pacific: Cancer Immunotherapy Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 48: China: Cancer Immunotherapy Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 49: China: Cancer Immunotherapy Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 50: Japan: Cancer Immunotherapy Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 51: Japan: Cancer Immunotherapy Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 52: India: Cancer Immunotherapy Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 53: India: Cancer Immunotherapy Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 54: South Korea: Cancer Immunotherapy Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 55: South Korea: Cancer Immunotherapy Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 56: Australia: Cancer Immunotherapy Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 57: Australia: Cancer Immunotherapy Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 58: Indonesia: Cancer Immunotherapy Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 59: Indonesia: Cancer Immunotherapy Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 60: Others: Cancer Immunotherapy Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 61: Others: Cancer Immunotherapy Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 62: Europe: Cancer Immunotherapy Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 63: Europe: Cancer Immunotherapy Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 64: Germany: Cancer Immunotherapy Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 65: Germany: Cancer Immunotherapy Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 66: France: Cancer Immunotherapy Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 67: France: Cancer Immunotherapy Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 68: United Kingdom: Cancer Immunotherapy Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 69: United Kingdom: Cancer Immunotherapy Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 70: Italy: Cancer Immunotherapy Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 71: Italy: Cancer Immunotherapy Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 72: Spain: Cancer Immunotherapy Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 73: Spain: Cancer Immunotherapy Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 74: Russia: Cancer Immunotherapy Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 75: Russia: Cancer Immunotherapy Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 76: Others: Cancer Immunotherapy Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 77: Others: Cancer Immunotherapy Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 78: Latin America: Cancer Immunotherapy Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 79: Latin America: Cancer Immunotherapy Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 80: Brazil: Cancer Immunotherapy Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 81: Brazil: Cancer Immunotherapy Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 82: Mexico: Cancer Immunotherapy Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 83: Mexico: Cancer Immunotherapy Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 84: Others: Cancer Immunotherapy Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 85: Others: Cancer Immunotherapy Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 86: Middle East and Africa: Cancer Immunotherapy Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 87: Middle East and Africa: Cancer Immunotherapy Market: Breakup by Country (in %), 2023
  • Figure 88: Middle East and Africa: Cancer Immunotherapy Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 89: Global: Cancer Immunotherapy Industry: SWOT Analysis
  • Figure 90: Global: Cancer Immunotherapy Industry: Value Chain Analysis
  • Figure 91: Global: Cancer Immunotherapy Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Cancer Immunotherapy Market: Key Industry Highlights, 2023 and 2032
  • Table 2: Global: Cancer Immunotherapy Market Forecast: Breakup by Therapy Type (in Million US$), 2024-2032
  • Table 3: Global: Cancer Immunotherapy Market Forecast: Breakup by Application (in Million US$), 2024-2032
  • Table 4: Global: Cancer Immunotherapy Market Forecast: Breakup by End User (in Million US$), 2024-2032
  • Table 5: Global: Cancer Immunotherapy Market Forecast: Breakup by Region (in Million US$), 2024-2032
  • Table 6: Global: Cancer Immunotherapy Market: Competitive Structure
  • Table 7: Global: Cancer Immunotherapy Market: Key Players